What people report and what the cautions say.

The short version

TB-500 is the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4, studied mainly in cell and animal models where the full parent protein accelerates wound healing, supports cardiac and neural repair, and modulates inflammation ^{[1][3][6][8][25]}. No controlled human trial of TB-500 itself has been completed, so the human evidence base is thin. This page presents two things: first, what people in research-use communities actually report (clearly labeled as anecdotal, not clinical evidence); and second, the safety and risk considerations that emerge from the preclinical and regulatory record. For the detailed mechanism and published trial results, see the research page.

What people report

All of the following are anecdotal, not clinical evidence. These accounts come from research-use forums, athletic and biohacker community discussions, and research-supplier review pages — individual experiences, not results from placebo-controlled studies.

Very commonly reported benefits: Faster recovery from tendon, ligament and muscle injuries — the main reason people in research-use communities reach for TB-500. Less joint pain, stiffness and better range of motion after a few weeks.

Frequently to occasionally reported benefits: Improved overall flexibility and mobility; a vague sense of reduced inflammation or calmer post-workout soreness; faster healing of cuts and skin irritation.

Rarely reported benefits: Hair regrowth or thicker hair over four to eight weeks — a minor and inconsistent signal.

Adverse effects: Injection-site redness, swelling or aching is the most common complaint (very commonly reported) — typically mild and resolving within a day or two, consistent with injected peptides generally. Temporary tiredness or lethargy in the first few days is frequently reported, usually fading with continued use. Occasionally reported: brief head rush, lightheadedness or headache shortly after injecting; a mild flu-like feeling in the first one to two days. Rarely reported: nausea (more associated with larger amounts), a temporary heightened awareness of an existing injury in the first week or two, and short-lived mood changes.

Safety and cautions

The following cautions are drawn from the published preclinical and regulatory literature, not from personal reports.

Human safety data is essentially absent for TB-500 itself. No completed controlled human trial of the seven-amino-acid heptapeptide exists. A 2026 sports-medicine review of unapproved peptides concluded that compounds like TB-500 show promise in animal models but carry scarce human safety data and operate largely outside regulatory oversight ^[27]. The Phase I safety data that do exist — reassuring as they are — belong to full-length recombinant Tβ4 at IV doses up to 1,260 mg, a different molecule ^[13].

Theoretical cancer and tumor-growth concern. This is the safety risk that appears most consistently in the peer-reviewed literature on Tβ4. The parent protein is overexpressed in several cancers and has been linked in preclinical models to tumor metastasis and angiogenesis ^[28][29]. The same pro-migration, pro-blood-vessel properties that may aid tissue repair could, in principle, support tumor progression. This concern has not been directly measured for TB-500 in humans, but anyone with a current or past cancer, or a strong family cancer risk, is the group most often flagged in discussion of this theoretical risk.

Banned in competitive sport. TB-500 is prohibited by the World Anti-Doping Agency under both S2 (Peptide Hormones, Growth Factors) and S0 (Non-Approved Substances) of the WADA Prohibited List ^[30]. Anti-doping laboratories have developed LC-MS methods to detect TB-500 and its breakdown products in plasma and urine ^[30]. A positive test can end an athlete's eligibility regardless of any claimed recovery benefit.

Reported benefits may overstate what the peptide actually does. An honest animal study found a key null result: in dystrophin-deficient mice given long-term thymosin beta-4, the number of regenerating muscle fibers increased, but there were no improvements in muscle strength, heart function or fibrosis levels ^[31]. More histological regeneration did not translate into better function — a caution against assuming felt improvements reflect real structural repair.

TB-500 is a fragment, not the full Thymosin Beta-4 protein. The encouraging efficacy research was conducted almost entirely with the full 43-amino-acid parent protein. TB-500 preserves the actin-binding LKKTETQ motif but not most of the downstream signalling surface — PINCH-ILK-Akt, NF-κB binding, Meprin-α cleavage to Ac-SDKP, and Notch/VEGF/HIF-1α induction in endothelium — that the clinical and preclinical record actually measures ^[30][25]. Applying parent-protein results to the fragment is an extrapolation that has not been confirmed in head-to-head comparisons.

Research-grade product quality is not guaranteed. TB-500 sold for research use is not manufactured to medicine-grade standards. Identity, purity and peptide sequence can vary between suppliers. Analytical characterization work on TB-500 preparations exists partly because doping-control laboratories needed to characterize them ^[32]. Unknown purity adds risk that is separate from, and on top of, the peptide's own pharmacology.

Theoretical cautions in pregnancy, breastfeeding, surgery and clotting. Because Tβ4 influences basic processes like cell migration and blood-vessel formation — processes central to development and to platelet function — these populations are flagged as a precautionary matter in the absence of any human safety data. These are mechanism-based concerns, not documented findings in human studies of TB-500.